1887
  1. Home
  2. A-Z Publications
  3. Qatar Medical Journal
  4. Volume 2024, Issue 4
  5. Article
Volume 2024, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: Respiratory syncytial virus (RSV) is a highly contagious pathogen known for causing respiratory tract infections, particularly among pediatric and elderly patients. Its ability to induce outbreaks in both community and hospital settings underscores its substantial health burden. This review aims to provide a comprehensive understanding of RSV, including its biological and clinical aspects.

Methods: A comprehensive review of the literature was conducted by searching PubMed, Scopus, and Web of Science databases for relevant articles. Key topics included RSV virology, epidemiology, clinical findings, diagnostic methods, management approaches, and preventive strategies.

Results: This review encompasses the taxonomy and structure of RSV, including its genome and proteins. Various strains and their dominance patterns, alongside pathogenesis mechanisms, are explored. Diagnostic techniques such as nucleic acid amplification tests are discussed for their efficacy and accessibility. Supportive care remains the primary treatment, with antiviral therapies playing a limited role. Monoclonal antibody immunization and vaccination efforts offer promising avenues for RSV prevention. The impact of the COVID-19 pandemic on RSV epidemiology is also considered, along with the oncolytic potential of RSV in cancer treatment.

Conclusion: Advancements in understanding RSV virology, epidemiology, and clinical management have paved the way for improved diagnostic and preventive strategies. However, challenges remain in ensuring widespread access to diagnostics and effective treatments, particularly in resource-limited settings. Continued research and global collaboration are essential for addressing the ongoing impact of RSV and reducing its burden on public health.

© 2024 Al-leimon, Shihadeh, Yousef, Khraim, Siwwad, licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2024.56
2024-12-24
2025-01-09
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2024/4/qmj.2024.56.html?itemId=/content/journals/10.5339/qmj.2024.56&mimeType=html&fmt=ahah

References

  1. Heikkinen T, Ojala E, Waris M. Clinical and socioeconomic burden of respiratory syncytial virus infection in children. J Infect Dis. 2017Jan1; 215:(1):17–23. https://doi.org/10.1093/infdis/jiw475
     [Google Scholar]
  2. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al.. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2024Feb5; 360:(6):588–98. https://doi.org/10.1056/NEJMoa0804877
     [Google Scholar]
  3. Durigon EL, Botosso VF, de Oliveira DBL. Human respiratory syncytial virus: Biology, epidemiology, and control. Hum Virol Latin Am. 2017Jul19;235–54. https://doi.org/10.1007/978-3-319-54567-7_12
     [Google Scholar]
  4. Wang X, Li Y, Shi T, Bont LJ, Chu HY, Zar HJ, et al.. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: A systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024Mar30; 403:(10433):1241–53. https://doi.org/10.1016/S0140-6736(24)00138-7
     [Google Scholar]
  5. Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA, et al.. ICTV virus taxonomy profile: Pneumoviridae. J Gen Virol. 2017Dec1; 98:(12):2912. https://doi.org/10.1099/jgv.0.000959
     [Google Scholar]
  6. Jorquera PA, Anderson L, Tripp RA. Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis. Expert Rev Vaccines. 2016Feb1; 15:(2):173–87. https://doi.org/10.1586/14760584.2016.1115353
     [Google Scholar]
  7. Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017Jan1; 30:(1):277–319. https://doi.org/10.1128/CMR.00010-16
     [Google Scholar]
  8. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019Sep10; 366:l5021. https://doi.org/10.1136/bmj.l5021
     [Google Scholar]
  9. Gao Y, Raghavan A, Deng B, Lee J, Liang B. Optimal conditions for in vitro assembly of respiratory syncytial virus nucleocapsid-like particles. Viruses. 2023Feb1; 15:(2):344. https://doi.org/10.3390/v15020344
     [Google Scholar]
  10. Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: The influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci. 2017Aug6; 18:(8):1717. https://doi.org/10.3390/ijms18081717
     [Google Scholar]
  11. Gould PS, Easton AJ. Coupled translation of the second open reading frame of M2 mRNA is sequence dependent and differs significantly within the subfamily Pneumovirinae. J Virol. 2007Aug15; 81:(16):8488. https://doi.org/10.1128/JVI.00457-07
     [Google Scholar]
  12. Thornhill EM, Verhoeven D. Respiratory syncytial virus’s non-structural proteins: Masters of interference. Front Cell Infect Microbiol. 2020May19; 10:225. https://doi.org/10.3389/fcimb.2020.00225
     [Google Scholar]
  13. Zhou X, Jiang M, Wang F, Qian Y, Song Q, Sun Y, et al.. Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation. Front Immunol. 2023Jan10; 13:1084139. https://doi.org/10.3389/fimmu.2022.1084139
     [Google Scholar]
  14. Muñoz-Escalante JC, Comas-García A, Bernal-Silva S, Robles-Espinoza CD, Gómez-Leal G, Noyola DE. Respiratory syncytial virus A genotype classification based on systematic intergenotypic and intragenotypic sequence analysis. Sci Rep. 2019Dec1; 9:(1):20097. https://doi.org/10.1038/s41598-019-56552-2
     [Google Scholar]
  15. Peret TCT, Hall CB, Hammond GW, Piedra PA, Storch GA, Sullender WM, et al.. Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. J Infect Dis. 2000; 181:(6):1891–6. https://doi.org/10.1086/315508
     [Google Scholar]
  16. Fan R, Fan C, Zhang J, Wen B, Lei Y, Liu C, et al.. Respiratory syncytial virus subtype ON1/NA1/BA9 predominates in hospitalized children with lower respiratory tract infections. J Med Virol. 2017Feb1; 89:(2):213. https://doi.org/10.1002/jmv.24619
     [Google Scholar]
  17. Auksornkitti V, Kamprasert N, Thongkomplew S, Suwannakarn K, Theamboonlers A, Samransamruajkij R, et al.. Molecular characterization of human respiratory syncytial virus, 2010–2011: Identification of genotype ON1 and a new subgroup B genotype in Thailand. Arch Virol. 2014Mar; 159:(3):499–507. https://doi.org/10.1007/s00705-013-1773-9
     [Google Scholar]
  18. Khor CS, Sam IC, Hooi PS, Chan YF. Displacement of predominant respiratory syncytial virus genotypes in Malaysia between 1989 and 2011. Infect Genet Evol. 2013Mar; 14:(1):357–60. https://doi.org/10.1016/j.meegid.2012.12.017
     [Google Scholar]
  19. Baek YH, Choi EH, Song MS, Pascua PNQ, Kwon H-il, Park SJ, et al.. Prevalence and genetic characterization of respiratory syncytial virus (RSV) in hospitalized children in Korea. Arch Virol. 2012Jun; 157:(6):1039–50. https://doi.org/10.1007/s00705-012-1267-1
     [Google Scholar]
  20. Dapat IC, Shobugawa Y, Sano Y, Saito R, Sasaki A, Suzuki Y, et al.. New Genotypes within respiratory syncytial virus group B genotype BA in Niigata, Japan. J Clin Microbiol. 2010Sep; 48:(9):3423. https://doi.org/10.1128/JCM.00646-10
     [Google Scholar]
  21. Saravanos GL, Ramos I, Britton PN, Wood NJ. Respiratory syncytial virus subtype circulation and associated disease severity at an Australian paediatric referral hospital, 2014–2018. J Paediatr Child Health. 2021Aug1; 57:(8):1190–5. https://doi.org/10.1111/jpc.15419
     [Google Scholar]
  22. Chen X, Zhu Y, Wang W, Li C, An S, Lu G, et al.. A multi-center study on Molecular Epidemiology of Human Respiratory Syncytial Virus from Children with Acute Lower Respiratory Tract Infections in the Mainland of China between 2015 and 2019. Virol Sin. 2021Dec1; 36:(6):1475. https://doi.org/10.1007/s12250-021-00430-7
     [Google Scholar]
  23. Leung NHL. Transmissibility and transmission of respiratory viruses. Nat Rev Microbiol. 2021Mar22; 19:(8):528–45. https://doi.org/10.1038/s41579-021-00535-6
     [Google Scholar]
  24. Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: A comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023Mar19; 15:(3):e36342. https://doi.org/10.7759/cureus.36342
     [Google Scholar]
  25. Van Royen T, Rossey I, Sedeyn K, Schepens B, Saelens X. How RSV proteins join forces to overcome the host innate immune response. Viruses. 2022Feb17; 14:(2):419. https://doi.org/10.3390/v14020419
     [Google Scholar]
  26. Weber F. Antiviral innate immunity: Introduction. Encyclopedia Virol. 2021Jan1; 1–5:577. https://doi.org/10.1016/B978-0-12-809633-8.21290-9
     [Google Scholar]
  27. Binns E, Tuckerman J, Licciardi P V., Wurzel D. Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions. J Paediatr Child Health. 2022Oct1; 58:(10):1741–6. https://doi.org/10.1111/jpc.16197
     [Google Scholar]
  28. Dervaux B, Van Berleere M, Lenne X, Wyckaert M, Dubos F. Impact of RSV test positivity, patient characteristics, and treatment characteristics on the cost of hospitalization for acute bronchiolitis in a French university medical center (2010–2015). Front Pediatr. 2023Jul14; 11:1126229. https://doi.org/10.3389/fped.2023.1126229
     [Google Scholar]
  29. Bianchini S, Silvestri E, Argentiero A, Fainardi V, Pisi G, Esposito S. Role of respiratory syncytial virus in pediatric pneumonia. Microorganisms. 2020Dec1; 8:(12):1–14. https://doi.org/10.3390/microorganisms8122048
     [Google Scholar]
  30. Toivonen L, Karppinen S, Schuez-Havupalo L, Teros-Jaakkola T, Mertsola J, Waris M, et al.. Respiratory syncytial virus infections in children 0–24 months of age in the community. J Infect. 2020Jan1; 80:(1):69–75. https://doi.org/10.1016/j.jinf.2019.09.002
     [Google Scholar]
  31. Niles D, Larsen B, Balaji A, Delaney D, Campos E, Bhattarai B, et al.. Retrospective review of clinical and chest X-ray findings in children admitted to a community hospital for respiratory syncytial virus infection. Clin Pediatr (Phila). 2018Dec1; 57:(14):1686–92. https://doi.org/10.1177/0009922818795902
     [Google Scholar]
  32. Teck KS, Mac Guad R, Van Rostenberghe AH, Hua GS. Prevalence, risk factors and clinical characteristics of respiratory syncytial virus-associated lower respiratory tract infections in Kelantan, Malaysia. J Med Virol. 2019Sep1; 91:(9):1608–15. https://doi.org/10.1002/jmv.25500
     [Google Scholar]
  33. Thomas E, Mattila JM, Lehtinen P, Vuorinen T, Waris M, Heikkinen T. Burden of respiratory syncytial virus infection during the first year of life. J Infect Dis. 2021Mar1; 223:(5):811–7. https://doi.org/10.1093/infdis/jiaa754
     [Google Scholar]
  34. Saha S, Pandey BG, Choudekar A, Krishnan A, Gerber SI, Rai SK, et al.. Evaluation of case definitions for estimation of respiratory syncytial virus associated hospitalizations among children in a rural community of northern India. J Glob Health. 2015; 5:(2):010419. https://doi.org/10.7189/jogh.05.020419
     [Google Scholar]
  35. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al.. Clinical practice guideline: The diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014Nov1; 134:(5):e1474–502. https://doi.org/10.1542/peds.2014-2742
     [Google Scholar]
  36. Okiro EA, Ngama M, Bett A, Nokes DJ, et al.. The incidence and clinical burden of respiratory syncytial virus disease identified through hospital outpatient presentations in Kenyan Children. PLoS One. 2012; 7:(12):e52520. https://doi.org/10.1371/journal.pone.0052520
     [Google Scholar]
  37. Zhang XB, Liu LJ, Qian LL, Jiang GL, Wang CK, Jia P, et al.. Clinical characteristics and risk factors of severe respiratory syncytial virus-associated acute lower respiratory tract infections in hospitalized infants. World J Pediatr. 2014Dec17; 10:(4):360–4. https://doi.org/10.1007/s12519-014-0513-x
     [Google Scholar]
  38. Haddadin Z, Rankin DA, Lipworth L, Suh M, McHenry R, Blozinski A, et al.. Respiratory virus surveillance in infants across different clinical settings. J Pediatr. 2021Jul1; 234:164–71.e2. https://doi.org/10.1016/j.jpeds.2021.03.036
     [Google Scholar]
  39. Rankin DA, Haddadin Z, Lipworth L, Stahl AL, Fryzek J, Suh M, et al.. Comparison of clinical presentations and burden of respiratory syncytial virus in infants across three distinct healthcare settings in Davidson County, Tennessee. Ther Adv Infect Dis. 2022; 9:20499361221112171. https://doi.org/10.1177/20499361221112171
     [Google Scholar]
  40. Ng KF, Tan KK, Sam ZH, Ting GSS, Gan WY, et al.. Epidemiology, clinical characteristics, laboratory findings and severity of respiratory syncytial virus acute lower respiratory infection in Malaysian children, 2008-2013. J Paediatr Child Health. 2017Apr1; 53:(4):399–407. https://doi.org/10.1111/jpc.13375
     [Google Scholar]
  41. Rosas-Salazar C, Chirkova T, Gebretsadik T, Chappell JD, Peebles RS, Dupont WD, et al.. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): A population-based, prospective birth cohort study. Lancet. 2023May20; 401:(10389):1669–80. https://doi.org/10.1016/S0140-6736(23)00811-5
     [Google Scholar]
  42. Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al.. Respiratory syncytial virus infection-associated hospitalization in adults: A retrospective cohort study. BMC Infect Dis. 2014Dec13; 14:(1):1–7. https://doi.org/10.1186/s12879-014-0665-2
     [Google Scholar]
  43. Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al.. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults ≥60 years old. Open Forum Infect Dis. 2018Dec1; 5:(12):ofy316. https://doi.org/10.1093/ofid/ofy316
     [Google Scholar]
  44. Sundaram ME, Meece JK, Sifakis F, Gasser RA, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged = 50 years: Clinical characteristics and outcomes. Clin Infect Dis. 2014Feb; 58:(3):342–9. https://doi.org/10.1093/cid/cit767
     [Google Scholar]
  45. Panayiotou C, Richter J, Koliou M, Kalogirou N, Georgiou E, Christodoulou C. Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010-2013): Age distribution, seasonality and association between prevalent genotypes and disease severity. Epidemiol Infect. 2014Nov17; 142:(11):2406–11. https://doi.org/10.1017/S0950268814000028
     [Google Scholar]
  46. Laham FR, Mansbach JM, Piedra PA, Hasegawa K, Sullivan AF, Espinola JA, et al.. Clinical profiles of respiratory syncytial virus subtypes A and B among children hospitalized with bronchiolitis. Pediatr Infect Dis J. 2017Aug1; 36:(8):808–10. https://doi.org/10.1097/INF.0000000000001596
     [Google Scholar]
  47. Espinosa Y, Martín CS, Torres AA, Farfán MJ, Torres JP, Avadhanula V, et al.. Genomic loads and genotypes of respiratory syncytial virus: Viral factors during lower respiratory tract infection in Chilean hospitalized infants. Int J Mol Sci. 2017Mar21; 18:(3):654. https://doi.org/10.3390/ijms18030654
     [Google Scholar]
  48. Midulla F, Nenna R, Scagnolari C, Petrarca L, Frassanito A, Viscido A, et al.. How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis. J Infect Dis. 2019Jan29; 219:(4):526–34. https://doi.org/10.1093/infdis/jiy496
     [Google Scholar]
  49. Rodriguez-Fernandez R, Tapia LI, Yang CF, Torres JP, Chavez-Bueno S, Garcia C, et al.. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. J Infect Dis. 2017Jan1; 217:(1):24–34. https://doi.org/10.1093/infdis/jix543
     [Google Scholar]
  50. Huang S, Chen J, Wang J, Zhao Y, Cong J, Wang Y, et al.. Original article application of MRT-qPCR for pathogen detection of lower respiratory tract infection. Am J Transl Res. 2022; 14:(5):3311–8.
    [Google Scholar]
  51. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: Comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002; 40:(3):817. https://doi.org/10.1128/JCM.40.3.817-820.2002
     [Google Scholar]
  52. Shirato K, Nao N, Kawase M, Kageyama T. An ultra-rapid real-time RT-PCR method using PCR1100 for detecting human orthopneumovirus. Jpn J Infect Dis. 2020; 73:(6):465–8. https://doi.org/10.7883/yoken.JJID.2020.182
     [Google Scholar]
  53. Cheng A, Riedel S, Arnaout R, Kirby JE. Verification of the Abbott Alinity m Resp-4-Plex assay for detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus. Diagn Microbiol Infect Dis. 2022Feb1; 102:(2):115575. https://doi.org/10.1016/j.diagmicrobio.2021.115575
     [Google Scholar]
  54. Zhen W, Manji R, Smith E, Wuitschick J, Lucic D, Berry GJ. Evaluation of the Alinity m Resp-4-Plex assay for the detection of severe acute respiratory syndrome coronavirus 2, influenza A virus, influenza B virus, and respiratory syncytial virus. Microbiol Spectr. 2022Feb23; 10:(1):e0109021. https://doi.org/10.1128/spectrum.01090-21
     [Google Scholar]
  55. Abdel-Moneim AS, Shehab GM, Alsulaimani AA, Al-Malky MIR. Development of TaqMan RT-qPCR for the detection of type A human respiratory syncytial virus. Mol Cell Probes. 2017Jun1; 33:16–9. https://doi.org/10.1016/j.mcp.2017.02.006
     [Google Scholar]
  56. Yan Y, Luo JY, Chen Y, Wang HH, Zhu GY, He PY, et al.. A multiplex liquid-chip assay based on Luminex xMAP technology for simultaneous detection of six common respiratory viruses. Oncotarget. 2017; 8:(57):96913–23. https://doi.org/10.18632/oncotarget.18533
     [Google Scholar]
  57. Hu T, Ke X, Li W, Lin Y, Liang A, Ou Y, et al.. CRISPR/Cas12a-enabled multiplex biosensing strategy via an affordable and visual nylon membrane readout. Adv Sci (Weinh). 2023Jan13; 10:(2):e2204689. https://doi.org/10.1002/advs.202204689
     [Google Scholar]
  58. Hongdan G, Yao D, Qiang C, Meng H, Xiaorong L, Zhihao X, et al.. A multiplex recombinase polymerase amplification assay combined with CRISPR/Cas12a for the detection of respiratory syncytial virus and respiratory adenovirus. J Int Med Res. 2024Jan1; 52:(1):3000605231223083. https://doi.org/10.1177/03000605231223083
     [Google Scholar]
  59. Chen C, Li X-N, Li G-X, Zhao L, Duan S-X, Yan T-F, et al.. Use of a rapid reverse-transcription recombinase aided amplification assay for respiratory syncytial virus detection. Diagn Microbiol Infect Dis. 2018Feb1; 90:(2):90–5. https://doi.org/10.1016/j.diagmicrobio.2017.10.005
     [Google Scholar]
  60. Eboigbodin KE, Moilanen K, Elf S, Hoser M. Rapid and sensitive real-time assay for the detection of respiratory syncytial virus using RT-SIBA(r). BMC Infect Dis. 2017Feb10; 17:(1):134. https://doi.org/10.1186/s12879-017-2227-x
     [Google Scholar]
  61. Kukushkin V, Ambartsumyan O, Subekin A, Astrakhantseva A, Gushchin V, Nikonova A, et al.. Multiplex lithographic SERS aptasensor for detection of several respiratory viruses in one pot. Int J Mol Sci. 2023May1; 24:(9):8081. https://doi.org/10.3390/ijms24098081
     [Google Scholar]
  62. Tien TTT, Park H, Tuong HT, Yu ST, Choi DY, Yeo SJ. Development of a rapid fluorescent immunochromatographic test to detect respiratory syncytial virus. Int J Mol Sci. 2018Oct2; 19:(10):3013. https://doi.org/10.3390/ijms19103013
     [Google Scholar]
  63. Bhandary R, Boloor R. Detection of respiratory syncytial virus using direct fluorescent antibody assay in paediatric patients with acute respiratory tract infection. J Clin Diagn Res. 2016Jun1; 10:(6):DC10–2. https://doi.org/10.7860/JCDR/2016/17530.8044
     [Google Scholar]
  64. Prendergast C, Papenburg J. Rapid antigen-based testing for respiratory syncytial virus: Moving diagnostics from bench to bedside? Future Microbiol. 2013; 8:(4):435–44. https://doi.org/10.2217/fmb.13.9
     [Google Scholar]
  65. Sun Y, Deng J, Qian Y, Zhu R, Wang F, Tian R, et al.. Laboratory evaluation of rapid antigen detection tests for more-sensitive detection of respiratory syncytial virus antigen. Jpn J Infect Dis. 2019; 72:(6):394–8. https://doi.org/10.7883/yoken.JJID.2018.528
     [Google Scholar]
  66. Huang JD, Wang H, Power U, McLaughlin JA, Nugent C, Rahman E, et al.. Detecting respiratory viruses using a portable NIR spectrometer-A preliminary exploration with a data driven approach. Sensors (Basel). 2024Jan1; 24:(1):308. https://doi.org/10.3390/s24010308
     [Google Scholar]
  67. Zhang W, Cui L, Wang Y, Xie Z, Wei Y, Zhu S, et al.. An integrated ddPCR lab-on-a-disc device for rapid screening of infectious diseases. Biosensors (Basel). 2023Dec21; 14:(1):2. https://doi.org/10.3390/bios14010002
     [Google Scholar]
  68. Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, et al.. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018Mar1; 7:(1):87–120. https://doi.org/10.1007/s40121-018-0188-z
     [Google Scholar]
  69. Barr R, Green CA, Sande CJ, Drysdale SB. Respiratory syncytial virus: Diagnosis, prevention and management. Ther Adv Infect Dis. 2019; 6:1–9. https://doi.org/10.1177/2049936119865798
     [Google Scholar]
  70. Domachowske JB, Anderson EJ, Goldstein M. The future of respiratory syncytial virus disease prevention and treatment. Infect Dis Ther. 2021Mar1; 10:(Suppl 1):47. https://doi.org/10.1007/s40121-020-00383-6
     [Google Scholar]
  71. Verwey C, Dangor Z, Madhi SA. Approaches to the prevention and treatment of respiratory syncytial virus infection in children: Rationale and progress to date. Paediatr Drugs. 2024Mar; 26:(2):101–2. https://doi.org/10.1007/s40272-023-00606-6
     [Google Scholar]
  72. Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: New perspectives for management and treatment. J Pediatr (Rio J). 2017Nov1; 93:(Suppl 1):75–83. https://doi.org/10.1016/j.jped.2017.07.003
     [Google Scholar]
  73. Marcelin JR, Wilson JW, Razonable RR. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014; 16:(2):242–50. https://doi.org/10.1111/tid.12194
     [Google Scholar]
  74. Kalergis AM, Soto JA, Gálvez NMS, Andrade CA, Fernandez A, Bohmwald K, et al.. Pharmacological management of human respiratory syncytial virus infection. Expert Opin Pharmacother. 2020; 21:(18):2293–303. https://doi.org/10.1080/14656566.2020.1806821
     [Google Scholar]
  75. Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018Apr1; 20:(2):e12844. https://doi.org/10.1111/tid.12844
     [Google Scholar]
  76. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, et al.. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014Aug21; 371:(8):711–22. https://doi.org/10.1056/NEJMoa1401184
     [Google Scholar]
  77. DeVincenzo J, Tait D, Efthimiou J, Mori J, Kim YI, Thomas E, et al.. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob Agents Chemother. 2020Jan27; 64:(2):e01884–19. https://doi.org/10.1128/AAC.01884-19
     [Google Scholar]
  78. Mackman RL, Sangi M, Sperandio D, Parrish JP, Eisenberg E, Perron M, et al.. Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015Feb26; 58:(4):1630–43. https://doi.org/10.1021/jm5017768
     [Google Scholar]
  79. Cunningham S, Piedra PA, Martinon-Torres F, Szymanski H, Brackeva B, Dombrecht E, et al.. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: A double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021Jan1; 9:(1):21–32. https://doi.org/10.1016/S2213-2600(20)30320-9
     [Google Scholar]
  80. Ibfelt T, Engelund EH, Schultz AC, Andersen LP. Effect of cleaning and disinfection of toys on infectious diseases and micro-organisms in daycare nurseries. J Hosp Infect. 2015Feb; 89:(2):109–15. https://doi.org/10.1016/j.jhin.2014.10.007
     [Google Scholar]
  81. Lei H, Li Y, Xiao S, Lin CH, Norris SL, Wei D, et al.. Routes of transmission of influenza A H1N1, SARS CoV, and norovirus in air cabin: Comparative analyses. Indoor Air. 2018May1; 28:(3):394–403. https://doi.org/10.1111/ina.12445
     [Google Scholar]
  82. Thomas RJ. Particle size and pathogenicity in the respiratory tract. Virulence. 2013Nov11; 4:(8):847. https://doi.org/10.4161/viru.27172
     [Google Scholar]
  83. Wang CC, Prather KA, Sznitman J, Jimenez JL, Lakdawala SS, Tufekci Z, et al.. Airborne transmission of respiratory viruses. Science. 2021Aug27; 373:(6558):eabd9149. https://doi.org/10.1126/science.abd9149
     [Google Scholar]
  84. Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, García-Lledó A, Hernández-Sampelayo T, et al.. Respiratory syncytial virus: A new era. Rev Esp Quimioter. 2024; 37:(2):134–48. https://doi.org/10.37201/req/147.2023
     [Google Scholar]
  85. Sun M, Lai H, Na F, Li S, Qiu X, Tian J, et al.. Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: A systematic review and network meta-analysis. JAMA Netw Open. 2023Feb1; 6:(2):e230023. https://doi.org/10.1001/jamanetworkopen.2023.0023
     [Google Scholar]
  86. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, Escobar Liquitay CM, Esteban I, Franco JVA. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021Nov16; 2021:(11):CD013757. https://doi.org/10.1002/14651858.CD013757.pub2
     [Google Scholar]
  87. Turalde-Mapili MWR, Mapili JAL, Turalde CWR, Pagcatipunan MR. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis. Front Pediatr. 2023Apr4; 11:1132740. https://doi.org/10.3389/fped.2023.1132740
     [Google Scholar]
  88. Mazur NI, Terstappen J, Baral R, Bardají A, Beutels P, Buchholz UJ, et al.. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023Jan1; 23:(1):e2–21. https://doi.org/10.1016/S1473-3099(22)00291-2
     [Google Scholar]
  89. Mazur NI, Löwensteyn YN, Terstappen J, Leusen J, Schobben F, Cianci D, et al.. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: A phase 1/2b randomized placebo-controlled trial. EClinicalMedicine. 2023Dec1; 66:102324. https://doi.org/10.1016/j.eclinm.2023.102324
     [Google Scholar]
  90. Bin Lu, Liu H, Tabor DE, Tovchigrechko A, Qi Y, Ruzin A, et al.. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015–2017. Sci Rep. 2019Mar7; 9:(1):1–10. https://doi.org/10.1038/s41598-019-40387-y
     [Google Scholar]
  91. Topalidou X, Kalergis AM, Papazisis G. Respiratory syncytial virus vaccines: A review of the candidates and the approved vaccines. Pathogens. 2023Oct1; 12:(10):1259. https://doi.org/10.3390/pathogens12101259
     [Google Scholar]
  92. See KC. Vaccination for respiratory syncytial virus: A narrative review and primer for clinicians. Vaccines. 2023Dec2; 11:(12):1809. https://doi.org/10.3390/vaccines11121809
     [Google Scholar]
  93. Roh EH, Fromen CA, Sullivan MO. Inhalable mRNA vaccines for respiratory diseases: A roadmap. Curr Opin Biotechnol. 2022Apr1; 74:104–9. https://doi.org/10.1016/j.copbio.2021.10.017
     [Google Scholar]
  94. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al.. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023Dec14; 389:(24):2233–44. https://doi.org/10.1056/NEJMoa2307079
     [Google Scholar]
  95. For Healthcare Professionals: RSV (Respiratory Syncytial Virus) | CDC.
    [Google Scholar]
  96. Rice E, Oakes DB, Holland C, Moore HC, Blyth CC. Respiratory syncytial virus in children: Epidemiology and clinical impact post-COVID-19. Curr Opin Infect Dis. 2023Dec1; 36:(6):522–8. https://doi.org/10.1097/QCO.0000000000000967
     [Google Scholar]
  97. Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie PM. Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine. 2023Jul1; 61:102089. https://doi.org/10.1016/j.eclinm.2023.102089
     [Google Scholar]
  98. Rao S, Armistead I, Messacar K, Alden NB, Schmoll E, Austin E, et al.. Shifting epidemiology and severity of respiratory syncytial virus in children during the COVID-19 pandemic. JAMA Pediatr. 2023Jul1; 177:(7):730–2. https://doi.org/10.1001/jamapediatrics.2023.1088
     [Google Scholar]
  99. Davitt E, Davitt C, Mazer MB, Areti SS, Hotchkiss RS, Remy KE. COVID-19 disease and immune dysregulation. Best Pract Res Clin Haematol. 2022Sep1; 35:(3):101401. https://doi.org/10.1016/j.beha.2022.101401
     [Google Scholar]
  100. Samadi M, Mokhtari-Azad T, Nejati A, Norooz-Babaei Z, Foroushani AR, Haghshenas MR, et al.. The antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms. BMC Cancer. 2023Dec1; 23:(1):803. https://doi.org/10.1186/s12885-023-11326-y
     [Google Scholar]
  101. Salimi V, Tavakoli-Yaraki M, Mahmoodi M, Shahabi S, Gharagozlou MJ, Shokri F, et al.. The oncolytic effect of respiratory syncytial virus (RSV) in human skin cancer cell line, A431. Iran Red Crescent Med J. 2013; 15:(1):62. https://doi.org/10.5812/ircmj.4722
     [Google Scholar]
  102. Choi SH, Park BK, Lee KW, Chang J, Lee Y, Kwon HJ. Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines. BMB Rep. 2015; 48:(10):565–70. https://doi.org/10.5483/bmbrep.2015.48.10.268
     [Google Scholar]
  103. Echchgadda I, Chang TH, Sabbah A, Bakri I, Ikeno Y, Hubbard GB, et al.. Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): Consequences of deficient interferon-dependent antiviral defense. BMC Cancer. 2011Jan28; 11:43. https://doi.org/10.1186/1471-2407-11-43
     [Google Scholar]
/content/journals/10.5339/qmj.2024.56
Loading
  • Article Type: Review Article
Keyword(s): Nirsevimab, pneumonia, Respiratory syncytial virus and RSV vaccine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error